Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression

DelBello, Melissa P.; Kadakia, Aditi; Heller, V.; Singh, Rajpal; Hagi, Katsuhiko; Nosaka, Tadashi; Loebel, Antony

doi:10.1016/j.jaac.2021.03.021

Cited by 19 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients 1 and 3 received lurasidone as the first choice option, while for patients 2 and 4, lurasidone was prescribed after previous antipsychotic treatments. These results are in line with previous observations, in which lurasidone is an effective treatment option for both antipsychoticnaïve adolescents diagnosed with schizophrenia and adolescents previously treated with antipsychotic medication, on positive and negative symptoms [55][56][57], with greater efficacy in the drug-naive patient group than patients previously treated. Costamagna et al, noted an onset of improvement on lurasidone as early as week 1, and it was consistently observed from weeks 2 to 6 across the 40-160-mg/d dose range in 537 adolescents and young adults with schizophrenia in pooled post hoc analysis of double-blind, placebo-controlled 6-week studies [58].…”

Section: Discussionsupporting

confidence: 92%

Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report

Ricci

Martinotti

Berardis³

et al. 2022

IJERPH

View full text Add to dashboard Cite

Background: Lurasidone is an atypical antipsychotic approved for the acute and maintenance treatment of schizophrenia. Recently, lurasidone was also extended FDA approval for adults with major depressive episodes associated with bipolar I disorder (bipolar depression), as either a monotherapy or as adjunctive therapy with lithium or valproate. The use of low doses of atypical antipsychotics is an essential component of early intervention in psychosis, but little has yet been studied on first episode cannabis-induced psychosis. For its particular performance and tolerability, lurasidone is becoming an important option for the treatment of first-episode psychosis in youth. Case presentation four patients experiencing first cannabis-induced psychotic episode were treated with lurasidone. In all patients, there was an improvement in the clinical picture of psychosis. The recovery was positive, not only with the remission of positive and negative symptoms, but also regarding disruptive behaviour, with the return of functioning. All the patients were treated with lurasidone, with a target dose of 74–128 mg/day. No significant side effects were reported. Conclusion: There are non-controlled studies for the use of lurasidone in first episode psychosis cannabis induced. These findings suggest that lurasidone is an atypical antipsychotic beneficial in this clinical picture. Treatment with medium-high doses of lurasidone could be effective and tolerable in this phase of the disorder. Randomized control trials with longer follow-up are recommended to confirm these positive results.

show abstract

Section: Discussionsupporting

confidence: 92%

Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report

Ricci

Martinotti

Berardis³

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…The key secondary efficacy endpoint was mean change from baseline to week 6 in the Clinical Global Impressions Bipolar Scale (CGI-BP-S) assessment, which rates severity of depression on a 7-point scale. 20 Additional secondary efficacy assessments included the 16-item, self-rated Quick Inventory of Depressive Symptomatology (QIDS-SR 16 ), 21 Hamilton Anxiety Rating Scale (HAM-A), 22 Sheehan Disability Scale (SDS), 23 and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF). 24…”

Section: Efficacy Assessmentsmentioning

confidence: 99%

“…The proportion of patients in the combined adjunctive groups who met a priori responder criteria was significantly higher for treatment with lurasidone versus placebo on the week 6 observed case analysis (61.8% vs 44.3%; P < 0.001; NNT = 6 [95% CI, 3-13]) and on the week 6 LOCF-endpoint analysis (55.0% vs 39.6%; P = 0.001; NNT = 7 [95% CI, [4][5][6][7][8][9][10][11][12][13][14][15][16]). The proportion of patients in the combined adjunctive groups who met remission criteria (MADRS ≤8) was significantly higher for treatment with lurasidone versus placebo on the week 6 observed case analysis (43.7% vs 23.2%; P < 0.0001; NNT = 5 [95% CI, 3-9]) and on the week 6 LOCF-endpoint analysis (37.6% vs 20.4%; P < 0.0001; NNT = 6 [95% CI, [3][4][5][6][7][8][9][10][11]).…”

Section: Efficacymentioning

confidence: 99%

“…[11][12][13] Currently, lurasidone and lumateperone are the only atypical antipsychotics approved by the Food and Drug Administration as a combination therapy with mood stabilizers (lithium or VPA) based on efficacy and safety results from placebo-controlled trials. [14][15][16] However, despite widespread use of combination therapies for short-term treatment, few controlled trials of combination therapy are available in patients with acute episodes of bipolar depression. Clearly, there is a need for more specific information on the benefit-risk profile of specific mood stabilizer combinations for the acute treatment of bipolar depression.…”

mentioning

confidence: 99%

“…The key difference in design between the 2 protocols was that, in the study of Suppes et al, 16 there were 2 cohorts of patients. The first cohort is a retrospective cohort that had been receiving lithium or VPA treatment at least 28 days or longer before randomization, identical to the Loebel et al adjunctive study cohort.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and Safety of Adding Lurasidone to Ongoing Therapy With Lithium or Valproate for the Treatment of an Acute Bipolar Depressive Episode

Tocco,

Mao

2024

J Clin Psychopharmacol

View full text Add to dashboard Cite

Purpose The aim of this study was to compare the efficacy and safety profile of lurasidone combined with either lithium or valproate, in the short-term treatment of patients with bipolar depression. Methods Data were pooled from two 6-week, double-blind, placebo-controlled trials of patients with bipolar depression on stable doses of lithium or valproate randomized to lurasidone (20–120 mg/d) or placebo. Efficacy measures included the Montgomery-Åsberg Depression Rating Scale, Clinical Global Impressions Bipolar Scale, and the Quick Inventory of Depressive Symptomatology via self-assessment and were analyzed using a mixed model for repeated measures approach. Results Notably larger week 6 effect sizes were observed when lurasidone was added to lithium, compared with when lurasidone was added to valproate, on 2 of the 3 depression outcome measures, Montgomery-Åsberg Depression Rating Scale total score (d = 0.45 vs 0.22) and Quick Inventory of Depressive Symptomatology via self-assessment (d = 0.63 vs 0.29); the efficacy advantage was smaller on the Clinical Global Impressions Bipolar Scale depression score (d = 0.34 vs 0.29). Similar adverse event profiles were observed for lurasidone treatment in combination with either lithium or valproate. The most frequently reported events (≥5%) in both groups were nausea, parkinsonism, somnolence, akathisia, and insomnia. Minimal changes in weight, lipids, and measures of glycemic control were observed during treatment with lurasidone combined with either lithium or valproate. Conclusions Lurasidone added to either lithium or valproate was found to be an effective treatment for bipolar depression, with a larger antidepressant effect observed when lurasidone was combined with lithium. There were no clinically meaningful differences in the safety or tolerability of lurasidone when used adjunctively with lithium or valproate.

show abstract

Manische Episode und bipolare affektive Störung

Holtmann,

Wewetzer

2023

Neuro-/Psychopharmaka Im Kindes- Und Jugendalter

View full text Add to dashboard Cite

Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression

Cited by 19 publications

References 34 publications

Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report

Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report

Efficacy and Safety of Adding Lurasidone to Ongoing Therapy With Lithium or Valproate for the Treatment of an Acute Bipolar Depressive Episode

Manische Episode und bipolare affektive Störung

Contact Info

Product

Resources

About